Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014205 · ClinicalTrials.gov registry record · Phase 1
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
A Phase 1 study, sponsored by Beijing InnoCare Pharma Tech Co..
- Active
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT04014205 is a Phase 1 study that is active but no longer recruiting, run by Beijing InnoCare Pharma Tech Co.. The registered enrollment target is 81 participants.
The verdict
NCT04014205, a Phase 1 study, is active but no longer recruiting, sponsored by Beijing InnoCare Pharma Tech Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).
Interventions
- DRUG Orelabrutinib (ICP-022)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04014205
The ClinicalTrials.gov registry entry for NCT04014205 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beijing InnoCare Pharma Tech Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Orelabrutinib (ICP-022) is the first listed.
NCT04014205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04014205 about?
NCT04014205 is a clinical study titled "A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies". This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).
What is the current status of trial NCT04014205?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2019-11-18. Estimated completion is 2026-06-30.
What interventions are being tested in trial NCT04014205?
The interventions under investigation include: Orelabrutinib (ICP-022) (DRUG).
Who is sponsoring clinical trial NCT04014205?
This trial is sponsored by Beijing InnoCare Pharma Tech Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.